Aspen Pharmacare Holdings Limited

Aspen reported first-half 2026 revenue of around ZAR 21 billion, down 4% year over year. Normalized EBITDA was just over ZAR 5 billion, down 13% from ZAR 5.8 billion, and normalized headline earnings were ZAR 5.75, down 21% from ZAR 7.24. Gross profit margin for the group declined to 45.4% from 47.6%, while commercial pharma gross margin stayed stable at 58.5% and its EBITDA margin improved to 29.2%. Operating cash flow was ZAR 3.6 billion, free cash flow was just under ZAR 2 billion, and net debt ended at ZAR 28.6 billion versus ZAR 31.2 billion in June 2025; leverage was 3.4x. Management said H2 2026 should be much stronger than H2 2025, and guidance was for commercial pharma to keep single-digit revenue growth and mid-single to double-digit EBITDA growth, manufacturing to be in line with the prior year, normalized HEPS to grow double digits, and EBITDA to be at least double the first-half run rate.

Stephen Saad framed the quarter as a reset year, saying Aspen is focusing on controllables: a solid commercial pharma base, a reshaped manufacturing footprint, and unlocking value through the APAC sale. He emphasized that GLP-1s are starting to show up in the numbers, that the mRNA contract loss is now mostly behind the company, and that the manufacturing restructuring is largely complete. His tone was candid and upbeat, especially on the idea that Aspen can emerge with lower debt, stronger cash flow, and a clearer valuation story.

Sean Capazorio highlighted the financial bridge to a stronger second half. He pointed to ZAR 3.6 billion of operating cash flow, nearly ZAR 2 billion of free cash flow, capex down to ZAR 1.6 billion from ZAR 2.6 billion, and net debt down to ZAR 28.6 billion, while also noting a 3.4x leverage ratio. He said commercial pharma revenue rose 4% in constant exchange rate terms and EBITDA rose 11% to ZAR 4.8 billion, with margins improving to 29.2%, while manufacturing EBITDA fell to about ZAR 0.2 billion from just under ZAR 1.3 billion due to the lost contract. He also outlined APAC proceeds of over ZAR 25 billion net, with an implied after-tax earnings impact around ZAR 1.85 billion after interest savings, and said tax rates were relatively stable at about 22.2% for total operations.

Analysts asked how much of commercial pharma growth came from GLP-1s and what happens when generics enter the market. Saad said Mounjaro is positioned at the high end of the market and is protected by long patents, while generics are more likely to affect lower-priced branded competitors and expand access to a different patient base, including potentially the public sector. Another question focused on NAV split and return on invested capital; management said manufacturing assets are meaningful but not easily separated from pharma support assets, and Saad acknowledged ROIC is not acceptable today but said the APAC divestment and manufacturing restructuring should improve it.